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Summary 
The current state of knowledge relating to nitrosamine 
carci nogenesi s is reviewed. An animal study is described 
which is designed to determine the dose-response pattern 
for two nitrosamines [diethyl and dimethyl nitrosamine] 
over a wide dose range using a large number of animals and 
dose-groups. 
The results of this study are given with details of 
tumours, their incidences, sites and pattern in time. These 
results are analysed to show that although there is an 
apparent threshold of response at low doses this is due to 
the failure of the animals to survive to a time when any 
incidence of tumours would be expected. It is also concluded 
that incidence only decreases with decreasing dose as a 
result of the interaction of normal mortality patterns with 
the incidence pattern of tumours. 
Finally the implications of some of the results are 
discussed and the analysis extrapolated to provide an 
estimate of risk for man from known exposure to low 
concentrations of ni trosami nes . 
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CHAPTER ONE 
INTRODUCTION 
2 
Nitrosamine Carcinogenesis 
N-Nitroso compounds are to be found in food [Gough et al., 
1977], in certain alcoholic beverages [Spiegelhalder et al., 
1979; Goff and Fine, 1979], in cigarette smoke [Brunneman 
et al., 1978; Webb and Gough, 1980], and in various industrial 
processes [Fan et al., 1977; Stephany at al., 1978; Webb and 
Gough, 1980; Fine, 1980] . Additionally N-nitroso compounds 
can be formed within the body by the interaction of nitrite 
and secondary or tertiary amines or amides [Lijinsky, 19613. 
The evidence for the carcinogenicity of many nitroso-compounds 
in a wide range of animal species (Schmahl, 1981; Bogovski and 
Bogovski, 1981] leads to concern about the consequences of the 
known human exposure to these compounds. The N-nitroso 
compounds can be conveniently divided into two broad cate- 
gories, the N-nitrosamines which require metabolic activation 
before demonstrating carcinogenic properties and the N-nitro- 
samides which do not require such activation. 
Presence of N-nitroso compounds in food is frequently 
correlated with the use of sodium nitrite as a preservative. 
The N-nitroso compounds arise from the interaction of the 
nitrite and secondary or tertiary amines present in the food 
[Challis, 1981). The production of some of these N-nitroso 
compounds, particularly N-nitroso pyrrolidine in bacon is 
significantly enhanced by cooking [Gough et al., 1978], 
although approximately 90% of that produced volatilises 
during the cooking process [Gough et al., 1976). Diets that 
contain no preformed N-nitroso compounds may give rise to 
nitrosated products following ingestion [Walters et al., 
19793. These are again formed from nitrite and secondary or 
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tertiary amines, although there is evidence that dietary 
nitrite may be supplemented by the conversion of nitrate to 
nitrite both by plant enzymes and bacteria [White, 19751. 
In addition to dietary sources of secondary or tertiary 
amines or amides there is much concern about the fate of many 
drugs which have such structures and are known to be nitro- 
sated 'in vivo' in a number of animal species [Lijinsky, 19811. 
Although some N-nitroso compounds are not carcinogenic 
their production in the body cannot be regarded as without 
risk as trans-nitrosation reactions are known to occur in which 
the N-nitroso group is transferred to a different secondary 
amine, possibly giving rise to a carcinogenic product 
[Dennis at al., 19793. 
The potential of the human exposure to these chemicals to 
produce cancer is unknown and in view of effects in animals is 
worthy of investigation. Before going on to explore alter- 
native ways of investigating this potential it is important 
to consider the nature of cancer and its possible origins. 
The Nature of Cancer 
Cancer is a collective name for a variety of proliferative 
lesions possessing certain common properties: 
A. GENETIC DAMAGE = The change present in the cells is 
heritable and generally irreversible and the lesion 
does not regress in the absence of the causative 
stimulus. 
B. INVASION - Surrounding tissue is invaded or 
infiltrated by cancer cells. 
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C. METASTASIS - cells from the original tumour may be 
transported to distant sites where they settle and 
give rise to secondary colonies of cancer cells. 
The main difference between a chemically-induced cancer 
and any other toxic lesion is its ability to progress in the 
absence of further stimulus. The persistence of the change 
together with its heritability is generally considered to 
indicate that the ultimate carcinogenic mechanism involves 
changes in the genetic material of affected cells. 
The changes in DNA commonly associated with treatment 
with chemical carcinogens are alkylations of nucleic acids. 
Particular sites on particular nucleic acids show a high 
frequency of alkylation [Faustman and Goodman, 19813. Although 
in certain cases there is a tendency for a correlation of 
alkylation at a specific site on DNA with carcinogen-potency 
at that site, this is not universally the case. The site of 
alkylation showing the best correlation with target specificity 
and potency is the alkylation of the 06 position of guanine 
[Loveless, 1969; Pegg, 19771. These workers demonstrated that 
a significant factor in determining site of carcinogen action 
was the rate of repair of the 0 6-alkylated guanine. However, 
as in many areas of research, it is one thing to demonstrate 
a correlation between two events, but is far more difficult 
to demonstrate a causative relationship between them. Thus, 
while 06 alkylation of guanine may play a part in chemical 
carcinogenesis it may not be the step or even the pathway 
that brings about cell transformation. 
This is in accord with a view expressed by Cairns [1981] 
who, in reviewing the role of mutation in carcinogenesis 
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concluded that the genetic changes involved in cancer pro- 
duction are major structural alterations, possibly involving 
changes in the expression of parts of the genome. While it 
is clear that the mutations which may result from local 
damage, such as alkylation, may contribute to the major 
structural alterations referred to, they are not sufficiently 
significant, in themselves, to bring about the changes in cell 
behaviour that are typical of cancer. 
It is conceivable that some parts of the genetic material 
are more susceptible to damage than others and there is some 
evidence that alkylation of chromosomes is not uniform 
[Faustman and Goodman, 19813. One theory of control of gene 
expression postulates the existence of control elements,, 
sequences of DNA which, according to their state permit or 
prevent subsequent genes being coded. If one of these con- 
trol elements were damaged by carcinogens then the effect is 
likely to be much greater than damage at other sites. Such an 
event might lead to expression of genes not normally typical 
of the cell type. This idea would tend to fit in with 
observations made by Klein [ 19813 in a review of work with 
transforming viruses. This review suggests that cell trans- 
formation may result from the activation of a single 'oncogene' 
which forms part of the DNA of all cells. 
Thus, in some way, the ability of all carcinogens to 
bind to DNA or to generate radicals which do so can bring about 
major changes in the genetic material which cause cell trans- 
formation. The precise mechanism awaits a greater under- 
standing of the normal processes of control of gene expression. 
If the only step in carcinogenesis was DNA damage then 
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cancer would follow exposure to carcinogens very rapidly. 
Even at the highest non-toxic doses of the most potent 
carcinogens known, some weeks must elapse between first 
treatment and appearance of the first tumour. In known 
human cases of chemical carcinogenesis, cancer does not 
usually appear until many years after first exposure. Thus, 
whatever change has taken place in the genetic material lies 
apparently dormant until triggered by other processes or 
events. These two stages have been defined as Initiation 
and Promotion. The carcinogen is essential for initiation 
and generally can act as a promoter, however, promotion may 
be achieved by a much wider range of stimuli. Recent work 
on autoxidative changes resulting from free-radical generation 
in the cells suggests a possible mechanism whereby the two 
stage process may be achieved. If it is assumed, as appears 
to be the case, that a cell with altered DNA continues, in 
the absence of other stimuli, to function as a relatively 
normal member of the population from which it is derived, then 
I the essential step to a cancer cell might be achieved by a 
gradual alteration of the rest of the cell to provide the 
environment in which the altered DNA exerts its transforming 
properties. Such an alteration of non-nuclear cell components 
is known to result from carcinogen treatment, with alkylation 
of a whole range of cellular macromolecules. One specific 
change that has been identified, following carcinogen treat- 
ment is abnormal glycoprotein synthesis [Warren et al., 1978). 
As glycoproteins form an essential part of cell membranes and 
particularly of cell-surface tissue-specific sites, they have 
a significant role in preserving cell and tissue identity. 
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It is conceivable that this change in the cell may be 
prevented or, at least repaired in cells with undamaged 
nuclei. In cells with altered DNA however these changes may 
accumulate until a suitable environment is created for the 
altered DNA to act to stimulate cell growth and division just 
as if the surrounding tissue did not exist. Some support for 
this idea comes from work on cultured cells. It is widely 
accepted that many cell cultures are more susceptible to cell 
transformation than the parent tissue and that such trans- 
formation occurs almost immediately after treatment with the 
carcinogen. It is possible that these cells in culture are 
not subject to the normal range of tissue-specific factors, 
and as such are closer to the state which may be achieved by 
Promotion. 
There is evidence that treatment with high doses of 
carcinogens kills some cells or groups of cells within an 
organ, while others which are then resistant to subsequent 
treatment with the carcinogen, survive. It may be that these 
'selected' cells are genetically altered and, if so, present 
ideal targets for the epi-genetic effects of the carcinogen. 
There is much evidence from the pattern of development of 
some epithelial tumours, from hyperplasia through benign to 
malignancy, for a gradual process of carcinogenesis rather 
than a number of dramatic steps or stages. Such a process 
could be the gradual loss of cell identity with increasing 
dominance of abnormal glycoproteins which eventually would 
allow a genetically altered cell to transform. 
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I Chemical Carcinogenesis 
Agents known to be capable of causing cancer are: 
a] Ionising and ultra-violet radiation. 
b] Reactive chemicals including free-radicals. 
c) Viruses. 
While much effort has been devoted to discovering viral 
origins for human cancer, this has produced little evidence 
for viruses as a major cause. Suspicion has therefore fallen 
upon chemicals, as a potential cause of many apparently 
'spontaneous' human cancers. 
The variety of chemicals known to be capable, at high 
doses, of inducing tumours in animals does nothing to allay 
the suspicions. The mechanisms by which chemical's with 
widely diverse structures bring about very similar changes 
in the target tissues is worthy of discussion, for it is 
based on an understanding of these mechanisms that any con- 
clusions concerning human exposure can be drawn. 
A number of examples of carcinogens are shown in 
figure 1.1. 
The first factor that all these different structures 
have in common is the requirement for metabolism, generally 
occurring on the endoplasmic reticulum. The postulated 
proximal carcinogens in each case are shown in figure 1 .2. 
Each of these is a highly active molecule which will tend 
to bind to cellular macromolecules or to generate radicals 
that do so. Thus a common feature of chemical carcinogens 
is the ability to give rise to covalently bound adducts of 
all cellular macromolecules including DNA. Certain molecules 
within the cell possess a great affinity for these active 
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molecules, and may, under normal circumstances act to reduce 
the formation of covalent adducts with other molecules. 
Examples of such 'scavengers' are glutathione, retinol and 
vitamin E. Other factors such as DNA repair may also act 
to alter the effect of a dose of carcinogen. While it is 
known that man is susceptible to certain chemical carcinogens 2 
this evidence arises from circumstances where exposure is 
high, such as occupational or drug treatment. There is still 
a need to discover what risk, if any, is posed by those 
chemicals, known to be capable of causing cancer in animals, 
and known to be present in the human environment. 
Methods of Determination of Risk to Man from Carcinogens 
An approach which attempts to study this problem directly 
is that of epidemiology. By studying cancer incidence in 
different populations it is possible firstly to decide 
whether any population faces a different risk of cancer from 
the rest. If so, some cause for this difference can be 
sought. While this approach is useful in suggesting associa- 
tions between particular habits or diets and cancer incidence 
there is little chance of ever deriving a certain cause and 
effect relationship. Thus it is known that populations in 
South America and parts of China who have high nitrate and 
nitrosamine intakes respectively also demonstrate unusually 
high incidences respectively of gastric and oesophageal 
cancer. While it is not possible to draw firm conclusions 
from this data due to the difficulty of isolating single 
factors, it must act to guide other experimental approaches. 
The main experimental method, at present, for determining 
13 
whether or not a chemical is a carcinogen is by administration 
over the life-span to laboratory animals C generally rats 
and/or mice], at doses ranging up to the highest dose 
compatible with normal growth and survival of treated 
animals. Interpretation of a positive result in such studies 
presents many problems, based in a general uncertainty as to 
the suitability of any animal species as a model for man, 
and much debate over the correct method of deriving quanti- 
tative conclusions for man from such data. However, short 
of experimenting on humans, the animal studies are the best 
method available, and by understanding the process involved, 
it is possible to minimise the uncertainty. 
Various short-term investigations designed to predict 
carcinogenic potential have been proposed and some have 
achieved usefulness, however such tests struggle to duplicate 
the results of animal studies and thus do not offer a better 
way of predicting human risk. Most such studies are based 
on detecting the mutagenicity of a chemical, a property which 
appears to be closely linked to its carcinogenic potential. 
In the future, studies of mutageni ci ty in different 
human populations may tell us more about risk of cancer but 
this data is not yet available and will not be for some time. 
Nitrosamines - Carcinogens for Animals 
The story of nitrosamine toxicity begins as do many others 
with an observation of the effects of human exposure. Two 
laboratory workers were found to have developed cirrhosis of 
the liver following approximately 10 months' exposure to 
di methylni trosamine [ DMN ] which was being used as a solvent. 
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This observation prompted investigations of acute and 
short-term toxicity by Barnes and Magee C19543. The animal 
species used in the acute investigations were rats, mice, 
rabbits, guinea-pigs and dogs. In all these species the 
LD50 appeared to be between 10 and 30 mg/kg. In all species 
the liver was the target organ, showing various degrees of 
damage accompanied by peritoneal exudate, haemorrhagic in the 
case of rats, dogs and guinea-pigs. Animals surviving a 
single dose for up to 10 days showed similar signs of hepatic 
damage. A repeated dose study was confined to rats given 
doses of 50,100 and 200 ppm in the diet for 110 days. The 
groups receiving 100 and 200 ppm died before the end of the 
study. 
The histological picture in all acute cases showed 
centrilobular necrosis with haemorrhage into the necrotic 
areas. Animals surviving the acute dose for more than 10 
days showed evidence of regeneration of liver tissue from 
the cells of the periportal areas. In the repeated dose 
study centrilobular necrosis persisted with some evidence 
of abnormal nuclear forms in the surviving periportal cells. 
The same authors in 1956 went on to study the longer 
term effects of DMN in rats and demonstrated its carcinogenic 
properties. A group of 10 male and 10 female rats were fed 
a diet containing 50 ppm DMN. A control group of 5 males 
and 5 females received basal diet. The first treated animal 
died after 27 wk of treatment and by wk 42 only one of this 
group remained alive. As in the acute studies, the only 
organ to be affected was the liver, where 19 of the 20 treated 
animals developed primary tumours. The main lesions seen in 
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the livers were classified as hepatomas which appeared to 
originate from hepatocytes and included a range of types 
from advanced hyperplastic nodules to metastasising ana- 
plastic tumours. A second type of lesion was encountered, 
described at autopsy as small translucent cysts. These 
were considered to be of biliary origin and to be a 
separate lesion from 'the hepatomas, being described as 
cystadenomata. 
Following these observations a large number of nitro- 
samines have been studied in a wide range of species. In mE 
instances, they are carcinogens each with specific target 
organs, in a given species, although the target organ for 
a single nitrosamine can vary from one species to another 
as illustrated in data prepared by Schmahl 01981) for 
di ethylni trosamine. 
Nitrosamines - Structure, Metabolism and Mechanism 
of Action 
All nitrosamines possess the following structure: 
N --- N -. 0 
R 2 
where RI and R2 are aryl or alkyl groups and may be 
identical, different, or part of a ring system. Some 
examples are given in figure 1.3. 
The lower members of the dialkyl series, together with 
some cyclic nitrosamines are steam-volatile, and can be 
quantitatively recovered from complex mixtures and body 
16 
FIGURE 1.3 SOME EXAMPLES 
CH3 
N-NO 
CHF 
DIME THYLNITROSAMINE 
I' 
N 
0 
N-NITROSOPIPERIDINE 
OF N-NITROSAMINES 
CH CH 
32 
ýN-NO 
CH3CH2 
DIETHYLNITROSAMIN[ 
\/ N 
i 
N 
0 
N- NITRO SOPYRROLI DINT 
17 
tissues and fluids for analysis. As quantitative extraction 
of the 'non-volatile' nitrosamines has not yet been achieved 
successfully most research is restricted to the volatiles. 
This is not too great a disadvantage as the most potent 
carcinogens are the two lowest members of the dialkyl series, 
diethylnitrosamine [DEN] and dimethylnitrosamine [DMN) . 
Studies of structure-activity relationships for nitro- 
samines have suggested correlations between carcinogenicity 
and water-hexane partition coefficients [W ishnok et al., 
19783 and chain-length or number of carbon atoms [Wishnok 
and Archer, 19763. These two factors may illustrate the 
effects of transport and metabolism respectively on the 
carcinogenic potency of a given nitrosamine. 
The most frequently studied nitrosamine metabolism is 
that of DMN. Despite many years of work by a large number 
of independent groups the metabolism of this nitrosamine is 
poorly understood. It is known that administration of DMN 
leads to alkylation of cell macromolecules, including DNA 
[Magee and Barnes, 19673, and that an administered dose is 
rapidly broken down to CO2 [Heath, 19621. As for many 
chemicals, it was suspected that the metabolism of nitrosa- 
mines involved an initial oxidation by enzymes of the 
microsomal mixed function oxidase system dependent upon 
cytochrome P450. However, experiments based on this supposi- 
tion failed to give entirely consistent and reproducible 
results [Lake et al ., 1974,1976J. Recent work by Lake et al. 
[1978] has pointed to a route for metabolism involving 
N-oxidation by an amine oxidase which is independent of 
cytochrome P 450. It is possible that this pathway runs in 
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parallel with a P450-dependent oxidation. Beyond this point 
it is postulated that degradation proceeds non-enzymically 
to yield carbonium ions which are the active alkylating 
species, along with formaldehyde, methanol and nitrogen. 
Although it has been a temptation for many researchers in 
this field to assume that the metabolism of DMN must proceed 
via an alkylating mechanism, it is clear that this does not 
need to be the major pathway. This view is supported by 
the results of Cottrell et al. [1977] who demonstrated in 
studies using 
15N-labelled 
DMN that production of nitrogen 
was only 5% of that expected if DMN were metabolised as 
predicted. More recent data [Milstein and Guttenplan, 1979; 
Kroeger-Koepke et al ., 19811 have concluded that nitrogen 
production is almost quantitatively what is expected. This 
anomaly awaits resolution. 
There is evidence from studies with inhibitors of amine 
oxidase activity that inhibition of this enzyme during DMN 
treatment affords protection from the carcinogenic properties 
of this nitrosamine [Hadjiolov, 1971; Schmahl et al., 1976; 
Weisburger et al. , 19741 . 
Thus, in summary, the main route of toxicity and carcino- 
genicity of nitrosamines is concluded to be the alkylation of 
cell components. It is therefore the rate at which the 
alkylating species is generated in each tissue which determines 
the target organ and the potency of each nitrosamine. 
Nitrosamines - Human Exposure and Hazard? 
There is no direct evidence for the carcinogenicity of 
any nitrosamine for man. There is, on the other hand, no 
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reason to believe that man is any less susceptible to the 
carcinogenic effects of nitrosamine than any other species 
studied. Human exposure to nitrosamines is composed of two 
elements. Firstly, the ingestion or absorbtion of preformed 
nitrosamines present in various foodstuffs, tobacco smoke 
and industrial chemicals. Secondly nitrosamines are formed 
in the body from secondary amines and nitrite. 
Highly sensitive and specific analytical techniques 
have demonstrated nitrosamines in many foods preserved with 
or containing nitrite [e. g. bacon, cheese, ham] [ Spi egelhalder 
et al., 1980] in alcoholic beverages [Spiegelhalder et al., 
1960) in tobacco smoke [Brunneman, 1900) industrial cutting 
oils [Webb and Gough, 1980) and a variety of other sources. 
The general exposure to preformed nitrosamines from dietary 
sources has been calculated to be 1.1 pg/day for DMN and 
0.1-15 pg/ day for N-nitroso pyrrolidine [NPYR] [Spiegelhalder 
19803; 1 )Jg/week for DMN and 3 pg/week for NPYR and N-nitroso- 
piperidine [NPIP] [Gough et al., 19781; 0.38 »g/day DMN 
[Stephany and Schuller, 1980). While there is some difference 
between these figures a range of 0.1 -1 j. ig/ day for DMN and 
other alkylnitrosamines and 0.1-15 »g/day for NPYR and NPIP 
includes all the figures. There is a contribution to nitro- 
samine intake from cigarette smoking and exposure to side- 
-stream cigarette smoke [Brunneman et al. , 1980] and from certain 
occupations such as those involving leather tanning, 
rocket-fuel production and tyre chemicals. Excluding these 
avoidable exposures an upper limit of 10 »g/day expressed as 
DMN should cover the average human exposure to preformed 
nitrosamines. 
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The other major source of nitrosamines in the general 
population is the in vivo production from dietary amines, 
and drugs combining with nitrite. Nitrosation of secondary 
and tertiary amines will proceed without enzyme assistance 
on incubation with sodium nitrite at low pH [Andrews at al., 
1960]. As these conditions may exist in the stomach a number 
of animal studies have been carried out to discover the effect 
of simultaneous dietary administration of several amine drugs 
and sodium nitrite [Li jinsky, 1981] . Not only was nitrosamine 
formation demonstrated but these studies also continued for 
long enough to show that the combination of amine and nitrite 
was, in some cases, carcinogenic. 
While these studies demonstrate that carcinogenic nitro- 
sami nes can be formed 'in vivo,, the concentration of nitrite 
is artificially high. Thiocyanate is known to be a powerful 
catalyst for nitrosation [Boyland and Walker, 19741 and is 
present in normal human gastric juice [Ruddell et al., 1977]. 
It is therefore conceivable that nitrosamines could be formed 
in the normal human stomach after ingestion of food or drugs 
containing tertiary or secondary amines. This formation would 
be considerably enhanced by the simultaneous ingestion of 
nitrite or nitrate. This formation is likely to be enhanced 
in individuals having a low basal level of acid secretion 
since this appears to be correlated with higher gastric 
nitrite concentration and colonisation of the stomach by 
bacteria capable of catalysing nitrosation [Ruddell et al., 
19763. Analysis of human urine samples has demonstrated the 
presence of low levels of nitrosamines [Kakizoe, 19791 while 
analysis of faecal samples detected no nitrosamines [L yang-ja 
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Lee, 1981). The detection of ni trosami nes in urine may lend 
support to the view that the urinary bladder represents a 
second potential site for 'in vivo' nitrosamine formation, 
particularly when infected [Radomski at al. , 1978] . 
It is likely that the rate-limiting factor in human 
'in vivo' nitrosamine formation is the nitrite concentration. 
Due to the ability of oral bacteria to catalyse nitrite 
formation from nitrate, it is likely that human populations 
most at risk from nitrosamines formed in vivo are those 
exposed to high dietary nitrite ancj/or nitrate concentrations. 
Evidence for such a connection has been generated in a study 
of a population in Colombia exposed to an unusually high 
nitrate intake, and known to have an exceptionally high 
incidence of gastric cancer. Hawksworth at al. C19741 detected 
only low levels of gastric nitrite in this population and 
concluded that high urinary nitrate levels were the source 
of nitrosamines which subsequently caused the gastric cancer. 
The precise course of events in this population has not been 
established. However, it is generally accepted that nitro- 
samine formation is a major contributary factor to the excess 
cancer risk [Tannenbaum, 19611. 
Thus, human exposure to nitrosamines is impossible to 
estimate accurately and is likely to vary considerably from 
one individual to another. It is unlikely that exposure 
would exceed a total of 100 jig/day from all sources. In any 
attempt to calculate risk for man from nitrosamine exposure 
the relative risks of exposure to 10 rg/ day and 100 1g/ day 
will be compared. 
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Nitrosamines as Model Chemical Carcinogens 
For many people cancer is a very emotive word, and 
the desire to see cancer conquered is very strong in our 
society. When well-known scientists indicate that up to BO% 
of cancer may have an environmental cause, and in the same 
breath identify a range of chemicals known to cause cancer, 
it is not surprising that many people believe that all 
cancer is caused by chemicals. 
This is clearly not true, however, the belief has 
generated considerable pressure to reduce exposure to 
carcinogens. Before this can be achieved, we must know which 
chemicals are carcinogens and which are the most potent. In 
this way attention can be directed at the major hazards. The 
evidence cited in the preceding pages for the carcinogenicity 
of many nitrosamines in a range of animals species, and their 
possible involvement in at least some human cancers identifies 
these chemicals as deserving of investigation. A number of 
questions exist relating to the sensitivity of man to these 
compounds compared with animal species studied, and the 
precise level of exposure. One general question is also 
worthy of consideration; this relates to the quantitative 
difference between all animal studies and likely human 
exposure and the possibility that at very low levels of 
exposure there is no effect. This possible 'Threshold' of 
effect is dependent upon one or a combination of the following: 
[i] Failure of transport mechanisms below a certain 
concentration. 
[iii Shift in metabolism to 100'/o detoxication at low doses. 
[iii) Immediate and total repair of cell damage. 
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In order to shed some light on the significance of 
nitrosamines as human carcinogens, some complete understanding 
of the effects in animals must be achieved. One part of this 
understanding is the clarification of the quantitative 
relationship beyween rate of exposure to the carcinogen and 
the incidence rate of the induced tumours over the widest 
possible dose-range. The following is an account of such a 
study carried out in rats, investigating the carcinogenicity 
of a wide range of doses of dimethyl and di ethylnitrosamine. 
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CHAPTER TWO 
STUDY DESIGN 
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Concept of Study 
Faced with a decision to carry out an animal study and 
finite space and funds, the effects of low doses of nitro- 
samines can be studied in one of two ways. 
The first approach is to expose a small number of groups 
of animals to the dose-levels of interest. The number of 
groups is limited by the available space, as the groups 
themselves must be large to detect the low expected 
incidence of tumours. 
The second approach is to measure the response of 
animals to a wide range of doses of nitrosamine. In this 
way the relationship between dose and response may be 
established, and the likely response at the low doses 
deduced from this relationship. 
Each approach has its merits and disadvantages. The 
first studies the problem directly, but the accurate 
detection of an increased incidence of tumours requires 
more animals than could be employed. The second approach 
is based, necessarily, on the assumption that a relationship 
established between dose and response at high doses will 
hold good at the dose-levels of interest. It was decided 
to use a large number of dose-groups spanning a wide range 
of dose, as this approach was considered to stand more chance 
of providing useable data, than the large-group low-dose 
study, which might provide no information at all. 
Selection of Species 
As the ultimate aim of this study is an understanding 
of human exposure it is necessary to ensure that the species 
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used makes this extrapolation as simple as possible. Two 
basic factors therefore affect species choice: 
a] Availability - the animals must be available in 
sufficient numbers from an adequately defined 
population. 
b) Experience - it is highly desirable that the value 
of the species selected, as a model for human 
carcinogenesis, is known. Similarly, the back- 
ground pathology in the species chosen should be 
well-established. 
These limit the choice of species to three; rat, mouse 
and hamster. Of these, the hamster has been used by 
relatively few workers and is not known to be of any better 
predictive value than rat or mouse. Mice are available in 
a much greater variety of strains than rats. However, the 
variability, between strains, in background incidence of a 
number of tumours makes the rat the species of choice for 
these studies, by default. 
The next stage of the process was to define the 
particular strain of rat that would be used. To aid this 
decision a number of further factors were considered: 
a) Inbred Strain - in an experiment setting out to 
quantify an already established response the aim 
is to minimise variability in the population 
studied. 
b) Experience - the strain must have been used in 
chronic studies, spanning at least 2 years, to 
provide the necessary background knowledge of 
spontaneous tumour incidences and age-related 
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c] Availability - sufficient animals must be 
available for the study. 
d) Low tumour incidence - it would be preferable 
that the chosen strain had a low spontaneous 
incidence of the tumour types likely to be 
induced by treatment. Similarly it would be 
preferable if the strain were not unusually 
susceptible to any specific type of tumour. 
The only strain that satisfied all the above conditions, at 
the time of designing this study, was the Colworth Inbred 
Wistar from Unilever Ltd., Colworth, Sharnbrook, Beds. 
Selection of Nitrosamines 
It was necessary to choose representative examples of 
this group of chemicals as it was impossible to study the 
whole range. Diethyl [DEN] and dimethyl [DMN] nitrosamines 
were selected as being the most potent carcinogens in the 
group while being, structurally, the simplest members of 
the dialkyl series. For similar reasons they have also been 
the subject of considerable study by a number of workers 
[Druckrey, 1967; Terracini et al. , 1967; Magee and Barnes, 
1956). 
Group Sizes, Dose-levels and Schedules 
Based on data from previous studies [Druckrey, 1967; 
Terracini, Magee and Barnes, 19671 it was decided to use a 
dose-range between 50 and 25,600 ppb in the diet. The 
lowest dose is considered to be of a similar magnitude to 
the highest doses encountered by man; whereas the highest 
dose is known to produce tumours in rats, but with minimal 
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toxic effect. 
The major limitation on the number of groups was the 
available space. Accommodation was available for approxi- 
mately 4,000 rats. Thus with a group size set at 50 of each 
sex, being the smallest number considered capable of giving 
a useful measure of response, 40 groups could be accommodated. 
It was decided that the study should contain a large control 
group to generate as much contemporary background data as 
possible. The design ultimately decided on was of a control 
group containing 240 males and 240 females and 15 dose-levels 
of each nitrosamine, each containing 60 males and 60 females, 
adding up to 4080 rats. The lowest dose shown to produce 
tumours by previous workers [Druckrey, 19673 was approximately 
1000 ppb in diet. As the establishment of a dose-response 
relationship depends on the availability of a measurable 
response it was decided to bias the dose-range so that ten 
of the groups received doses in excess of 1000 ppb. This 
was achieved as below: 
Original dose-groups 
25600 ppb 
Interpolated groups 
12800 ppb 
9600 ppb 
8000 ppb 
6400 ppb 
4800 ppb 
3200 ppb 
1600 ppb 
800 ppb 
400 ppb 
200 ppb 
100 ppb 
2 400 ppb 
4000 ppb 
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Preliminary investigations of the stability of DEN and 
DMN in diet at the highest of the above concentrations showed 
losses exceeding 20% of the added amount within 24 hours. 
Stability in water solution was found to be considerably 
better and therefore the drinking-water was selected as the 
route of administration. It was known from many previous 
studies that rats drink a greater weight of water each day 
than they consume diet. From historic data it was deter- 
mined that multiplication of the concentrations intended for 
dietary administration by 0.66 would give the concentration 
in the drinking water that would be likely to provide a 
similar mg/day dose, The resultant dose-levels were thus: 
33,66,132,264,528,1056,1584,2112,2640, 
3168,4224,5280,6336,8448,16896 ppb in the 
drinking-water. 
The numbers of animals required for this study were too 
large to consider starting the whole study at one time. It 
was therefore decided to divide the study, to ensure 
effective management at all stages. Each dose-group, 
including the controls was divided into 10 sub-groups such 
that each sub-group contained 24 controls of each sex and 6 
of each sex for each dose of each nitrosamine. _ 
Each sub-group commenced treatment on a different occasion 
as shown below: 
In sub-group 6 the female 16896 DEN group was omitted and 
the female 21 12 DEN group consisted of 12 animals. 
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Sub-group Day off 
birth 
Day of first 
treatment 
Age [days at 
first treatment 
1 1-11 48 37- 48 
2 15-25 60 35-45 
3 30-40 75 35-45 
4 44- 54 B9 35 - 45 
5 56-68 104 36-48 
6 86-96 133 37-47 
7 99-1 10 1 47 37- 48 
8 113-123 161 38-48 
9 127-137 1 75 38-48 
10 156-1 66 203 37-47 
The first two sub-groups were taken for interim kill at 
12 months and 18 months from the start of treatment, 
respectively. " All the remaining animals were allowed to 
continue until they qualified for autopsy, either by death, 
sickness, or positive palpation. Treatment continued until 
autopsy in all cases. Animals were kept in their original 
cages without regrouping for the whole study. The following 
observations were made for each animal during each week of 
the study: 
Body weight 
Presence of palpable abdominal lump 
General condition. 
For each cage of animals the amount of water/ solution 
consumed was measured weekly. 
Day 1 is defined as the earliest day of birth of 
sub-group 1. 
;, Results from the groups terminated at 12 and 18 months are 
excluded from further analysis. 
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At autopsy the following data was recorded: 
Date 
Dose-group 
Animal number 
Sex 
Reason for autopsy 
Details of all macroscopic 
abnormalities. 
On microscopic examination of all the tissues taken at 
autopsy details were recorded of all histopathological 
changes seen. 
Based on all the available information the most likely 
cause of death was determined for each animal. 
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CHAPTER THREE 
EXPERIMENTAL METHODS AND MANAGEMENT 
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ENVIRONMENT CONTROL 
Due to the extremely low concentrations of nitrosamine 
under investigation in this study, the diet, drinking-water, 
general accommodation and maintenance procedures for the 
animals were given much attention, in order to identify 
and minimise any additional variables. 
Animal Accommodation 
All rats were housed in cages constructed from stainless 
steel and polyethylene. These cages were held in racks, 
each containing fifteen cages. Excreta were collected on 
high wet strength kraft paper, held on trays beneath the 
cages. 
The animals were kept in four rooms of an animal unit 
given over specifically to this study. The division of the 
study between the rooms is shown in figure 3.1. Air was 
provided to the animal rooms at a rate sufficient to give 
15 air changes per hour in each room. The cages were arranged 
in the room in such a way that the air was always being 
drawn away from the control animals, thus minimising possible 
contamination. This air was filtered to remove particles 
down to I mp in size. Although the air supply unit contained 
no provision to reduce air temperature below ambient, the 
temperature of the animal rooms was maintained at 21 + 2°C., 
apart from a few isolated occasions when it reached 27 
°C C. 
Humidity was maintained between 50 and 80%. 
Lighting of the rooms was on a 12-hour light, 12-hour 
dark cycle. The light part of the cycle coincided with the 
working day. 
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Animals 
Rats were transported weekly in cardboard transport 
boxes with soft-wood shavings as bedding, from Colworth to 
BIBRA. Food and water were not provided in the transport 
boxes. Each box contained animals of a single sex weaned 
on a single day, and was marked with this date. 
On arrival at BIBRA the sex of each animal was checked 
and they were caged in groups of 10-15, each cage containing 
animals weaned on the same day. These cages were provided 
with pelletted diet [page 36) and distilled water. 
When sufficient animals had been collected for the 
next phase of the experiment to commence and acclimatised 
at BIBRA for at least 7 days, the following procedure was 
used to assign animals at random to treatment group: on 
each occasion of randomisation the animals were to be 
allocated to 31 treatment groups, one [control) required 24 
rats whereas all others required 6 rats. Lists of random 
sequences of numbers from I to 31 were generated for the 
purpose by Richard Peto [Oxford]. The lists were employed 
as below: 
A cage of rats was emptied into a clean plastic bucket. 
A rat was taken from the bucket and allocated to the 
treatment groups designated by the first number on the list. 
The tail of the rat was colour-coded as the first animal 
in that cage and the weaning date was recorded. The next 
animal was taken from the bucket and assigned to the 
treatment-group designated by the second number on the list 
etc. A different colour was used to mark the tail of the 
Ist, 2nd, 3rd, 4th, 5th and 6th rats in each cage. Once all 
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the cages contained the required number of rats the animals 
were permanently identified using an ear-punch code 
[Fig 3.2] . 
Animal Maintenance Procedures 
The paper used for collecting excreta was changed 
daily. All cages were washed on a 3-weekly rota. When 
animals were transferred from one cage to another, this was 
carried out so that only one cage was open at any one time. 
The cages for each treatment group were labelled with 
waterproof marker to ensure that there was no exchange of 
cages between groups. The coding system used was a com- 
bination of colours and numbers identified in Figure 3.1. 
The use of the coding is best illustrated by examples: 
4200 ppb DEN A figure 4 in black on a green background 
530 ppb DMN A figure 5 in black on a red background. 
Diet 
Three commercially available diets suitable for the 
maintenance of rats were analysed for content of steam- 
-volatile nitrosamines and aflatoxint The results of these 
analyses are shown in Table 3.1. 
At this stage it was discovered that future production 
of the Unilever diet was uncertain and this was withdrawn 
tThe invaluable assistance of the laboratory of the 
Government Chemist, and the Tropical Products Institute, in 
performing these analyses is gratefully acknowledged. 
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FIGURE 3.2 RODENT EAR MARKING CODE 
Tens Units Thousands Hundreds 
RLRL 
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1 
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002D 
2000 200 
Qo 
3 3000 300 
40 
D4 
4000 400 
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5000 500 
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6000,600 
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90 90 °9000 900 
D" 
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Table 3.1 Analysis of commercial rodent diet for 
ni trosami nes 
Diet Source DMN [ppb] Other nitrosamines [ppb] 
Spillers 5-20 N. D. 
Oxoid 20-100 N. D. 
Unilever 0-5 N. D. 
N. D. = None detected 
Table 3.2 Analysis of diet constituents for nitrosamines 
and mycotoxins 
Constituent Nitrosamines Aflatoxin and Ochratoxin 
Fish-meal 
Soya-meal 
50-250 ppb DMN 
N. D. 
N. D. 
N. D. 
N. D. = None detected 
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from consideration. The Spillers diet therefore offered the 
lowest nitrosamine content, but this was considered to be 
unacceptably high for this particular study. The protein 
source used in this diet was White Fish meal which has in 
the past been shown to contain nitrosamines [Koppang, 19743. 
Samples of this ingredient and of soya-bean meal, an 
alternative protein source, were analysed for ni trosami ne 
and aflatoxin content. The results are shown in Table 3.2. 
Substitution of the soya-bean meal for fish meal was 
then contemplated and, in conjunction with the research 
laboratories of Spillers, a diet was developed with this 
change in formulation. At the same time it was agreed that 
supplies of this diet would be maintained for the duration 
of the study. 
Each fresh batch of diet delivered was analysed for 
content of the contaminants shown in Table 3.3. For each 
contaminant a maximum permitted concentration was defined. 
These concentrations were arrived at after analysis of a 
sample of the diet and a review of the likely effect of each 
of the contaminants. At no time during the study did any 
batch of diet contain more than the concentration of 
contaminants shown in the table. 
The diet used was in the form of expanded pellets and 
was fed 'ad libitum' from hoppers on each cage. 
Drinking Water 
To avoid any interference with the study, by nitrate 
or nitrite normally present in tap-water, distilled water 
was used throughout, both in the preparation of solutions 
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Table 3.3 Maximum permissible concentrations of dietary 
contaminants 
Contaminant Maximum permitted concentration 
Ni trosami nes 5 ppb 
Nitrate 20 ppm 
Nitrite 0.5 ppm 
Aflatoxin & ochratoxin 5 ppb 
Polycyclic aromatic 
hydrocarbons 20 ppb 
DDT 250 ppb 
Polychlorinated 
biphenyls 500 ppb 
Mercury 7 ppb 
Lead 2 ppm 
BHT [added antioxidant] 10 ppm 
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and for administration to control animals. 
Distilled, water was produced by two Fi -stream 8 litre/hr 
stills. The output from these stills was fed into a 1000 
litre capacity high-density polyethylene storage tank. 
Water was drawn from the tank when required, through 
food-grade PVC tubing, using a centrifugal pump. The tank 
was regularly drained and cleaned, using fresh distilled 
water, to prevent accumulation of any contamination. 
ADMINISTRATION OF NITROSAMINES 
Nitrosamine solutions were prepared weekly, and the 
concentration of nitrosamine in each solution was checked 
before use [Walters et al., 19701. The volatile nature of 
the nitrosamines under study necessitated the development 
of procedures which minimised loss. The procedures for the 
preparation and dispensing of the solutions are described 
below. 
To ensure that the animals received the intended 
solutions all drinking water bottles were drained each week 
prior to filling. These quantities of effete solutions and 
some excess preparation resulted in the production of con- 
siderable volumes of waste solutions. A method of neutra- 
lising this waste was developed [Gangolli et al., 19741. 
Preparation of Solutions 
The solutions were prepared in three stages of dilution. 
All preparation of solutions was carried out in a room 
within the animal unit that was specifically designated for 
this purpose. This room housed the stills and the storage- 
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-tank described previously, together with a refrigerator 
for storage of nitrosamines and a fume-cupboard for the 
preparation of solutions. 
All mixing and dispensing operations were carried out 
in the fume-cupboard. Small volumes were dispensed with 
automatic pipettes using disposable tips, larger volumes 
with automatic dispensers. Solution preparation consisted 
of three stages, the first two of which were carried out 
using glass volumetric flasks. Mixing of solutions was by 
means of magnetic stirrers. Some of the containers used 
for the final solutions could not be accommodated in the 
fume-cupboard, and for these situations a system was employed 
which permitted handling of the solutions to continue in the 
fume-cupboard. This system of a funnel held in a retort- 
stand within the fume-cupboard, connected by tubing to a 
screw-on cap which fitted the container for the final 
solution. A second tube was led back from this cap to the 
fume-cupboard to provide an air-vent when the bottle was 
being filled. 
The procedure used for the preparation of solutions is 
described below: 
Stage 1 
Stock solution in distilled water sufficient to last 
for 3-4 weeks were prepared at a concentration of 5.3% v/ v. 
These solutions were stored in brown glass bottles at 40C C. 
Stage 2 
I litre of a second dilution in distilled water was 
prepared each week, the concentration depended on the volumes 
of final solution that were required, [e. g. a final volume 
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of 6 litres required 10.0 ml to be diluted to 1 litre]. At 
this stage the concentration was checked using a polaro- 
graphic technique [Walters et al. , 19703. 
Stage 3 
Volumes of second dilution as shown in Table 3.4 were 
dispensed into each final solution container and made up to 
volume with distilled water. The volumes of water added 
were measured using a flow meter calibrated in 10 ml 
divisions. These solutions were mixed, using a large 
magnetic stirrer, for ten minutes each. 
Once all the final solutions had been prepared a small 
sample of each was taken for analysis. 
Solutions were deemed acceptable for use if the analysed 
concentration was within 10% of that intended, with two 
exceptions. The dose levels, 1060 and 1590, and 2100 and 
2600 were allowed a deviation of only 5% from the intended 
concentration, to prevent overlap. 
All analyses were performed by the BIBRA Biological 
Chemistry department whose assistance is gratefully 
acknowledged. The polarograph technique [Walters at al., 
19703 was used to analyse all solutions of greater than 1 
ppm nominal concentration. The limit of detection for this 
technique did however, mean that it could not be used for 
solutions of nominal concentration less than I ppm. This 
problem was overcome in the following way: 
Sodium chloride was added to the 'second dilution' 
referred to above to give a ratio of 20 gm NaCl to 0.53 ml 
nitrosamine. The ratio was checked at the time of analysis 
of this solution. The concentration of nitrosamine in the 
44 
Table 3.4 Volumes of second dilution to be taken for the 
preparation of the final solutions 
Nominal concentration of 
final solution [ppb] 
Volume of second 
dilution [ml] 
33 0.5 
66 1.0 
130 2.0 
260 4.0 
530 8.0 
1060 16.0 
1580 24.0 
2100 32.0 
2600 40.0 
3200 48.0 
4200 64.0 
5300 80.0 
6300 96.0 
8400 128.0 
16900 256.0 
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low-dose solutions [those less than I ppm] was assumed to 
be correct if the appropriate concentration of sodium 
chloride was found to be present using an Atomic 
Absorption Spectrophotometer. At approximately 6-weekly 
intervals the accuracy of this procedure was checked by 
analysing the solutions of less than I ppm nominal concen- 
tration, using a gas-liquid chromatography technique 
[Alliston et al., 19723. Although this procedure could 
analyse solutions, at all concentrations used it was too 
slow for routine use. 
Dispensing of Nitrosamine Solutions 
The containers in which the final solutions were 
prepared were used to dispense these solutions into the 
animal drinking bottles. The bottles were filled in situ on 
the racks carrying the cages. The design of these dispensing 
containers is shown in Fig. 3.3[A] . 
Solutions were dispensed by applying positive pressure 
to the head space of the container. The air-pressure was 
developed by a pump fitted with a pressure release valve 
operating at 5 p. s. i. A fail-safe valve developed for the 
purpose [Fig. 3.3 (B]], and fitted to the output tubing 
enabled the bottles to be filled without spillage. 
Weekly emptying of the drinking-bottles was carried out 
using a container similar to that used for dispensing but 
with negative pressure applied to the head-space. 
Drinking-bottles 
The volatile nature of the ni trosami nes used in this 
study necessitated the development of an animal watering 
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FIGURE 3.3 DISPENSING SYSTEM FOR NITROSAMINE 
SOLUTIONS 
[A] DISPENSING CONTAINER 
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(I 
alt-safe valve 
(see below) 
[ ß] FAIL SAFE VALVE 
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Stainless steel spring 
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system which had minimal leakage but which also permitted 
assessment of the volume of water consumed. The system which 
was developed for this study is shown in Fig. 3.4. This 
consists of a 1.3 litre high-density polyethylene bottle 
fitted with a nylon cap, moulded to accept a short length 
of clear PVC tubing, linking the cap to a stainless-steel 
needle-valve [NKP TV25 Mk III. To provide an air-bleed a '/z 
inch diameter hole was drilled in the base of each bottle, 
and this was fitted with a No. 13 red rubber bung with a 19 
gauge syringe needle pushed through and cut off. 
The volume of water consumed by each cage of rats was 
measured twice weekly. Measurement was by means of an 
adhesive scale fixed to the side of each bottle. The volumes 
equivalent to the scale divisions were defined in calibration 
studies, the volume removed from the bottle being deter- 
minable with an accuracy of + 10 ml. This method of 
measurement did not rely on the scale being fixed in precisely 
the same position on each bottle, as it simply required the 
difference between two readings from the parallel region 
of the bottle. 
Each bottle for each cage was uniquely identified, a 
duplicate set being used when bottles were removed for 
washing. The method of identification is shown in Fig. 3.4. 
The bottles were fitted to the racking carrying the cages in 
an inverted position. The needle-valves were held in the 
racking to locate in eyelets in the rear of each cage, thus 
avoiding disturbance of the bottles on removal of the cages. 
Prior to use the storage characteristics of nitrosamine 
solutions in these bottles was investigated. The results 
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FIGURE 3.4 DRINKING BOTTLE DESIGN AND IDENTIFICATION 
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demonstrated some variation but all within 10% of the 
intended concentration. On the basis of these results it 
was decided that fresh nitrosamine solutions would be 
prepared only once each week. 
OBSERVATION OF ANIMALS AND PALPATION 
Each animal was weighed weekly and at this time was 
palpated for abdominal masses, particularly those of the 
liver. Each cage of animals was inspected daily. The 
palpation procedure is by its nature a subjective obser- 
vation, a method of maintaining consistency is detailed 
below. The procedure followed in the case of sick animals 
is also described. 
Palpation 
Each rat was palpated once weekly at the time of 
weighing. To avoid too much observer variation a programme 
was devised using a team of three individuals working as 
shown below: 
Palpater Week I 
A 1+ 
B2 
C 3+ 
Week 2 
2 
3 
1 
Week 3 
3 
1 
2 
Week 4 
1 
2 
3 
Study divided into 3 sub-groups containing 
approximately equal numbers from each treatment. 
If an animal was thought by one of the team to have a 
palpable lump a second member of the team was called in to 
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confirm this observation. When two of the team were agreed 
that an animal had a palpable lump, that animal was taken 
immediately for autopsy. 
Sick Rats 
The animals found to be sick were monitored closely. 
When a sick rat reached a state where it could not reasonably 
be expected to survive a further 24 hours, it was taken for 
autopsy, together with any others found dead on the s me day. 
In a number of rats large subcutaneous masses developed. 
When these reached dimensions sufficient to seriously impede 
movement, or if ulceration occurred, these animals were 
taken for autopsy. 
AUTOPSY PROCEDURES 
Live animals brought to autopsy were killed by 
exsanguination from the aorta under deep barbiturate 
anaesthesia. To avoid any possible exchange of tissue 
samples or other form of confusion autopsies were carried 
out sequentially unless numbers [e. g. interim kills] dictated 
otherwise. The objective of the autopsy was defined clearly 
as the identification of the likely cause of sickness or 
death. Thus attention was concentrated on the macroscopic 
examination and description of all possible tissues, and 
routine sampling confined to only a few organs as described 
below. 
Liver, kidneys, bladder, lungs, skull and oesophagus 
were taken from every animal together with any other tissue 
found to be abnormal. All tissues sampled were preserved 
in 10% buffered Formalin. 
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All livers were examined for abnormality and the 
presence and position of all lesions was recorded. Each lobe 
of the liver was sampled after cutting into slices of 
approximately 5 mm thickness, and examination of the cut 
surfaces, two slices of each lobe were fixed separately in 
labelled tubes, to permit close correlation of histological 
and macroscopic findings. 
Bladders were inflated with Formalin before removal to 
ensure fixation of the epithelium. Lungs were also inflated 
in situ with Formalin through the trachea, and then removed 
and fixed intact. 
Oesophagi were removed complete with pharynx and the base of 
the tongue, opened up to reveal the mucosal surface and 
fixed intact on stiff card with the serosal surface against 
the card. The general position of any nodules and their 
size was recorded. 
Skulls were fixed after removal of the brain and 
pituitary, and examination of the buccal cavity by cutting 
through one axis of the jaw. Ears were left in place so that 
identification could be checked if necessary. 
Spinal cords were examined in situ by trimming off the 
dorsal part of the neural arches with bone-nibblers. 
Tissues were stored in plastic pots and labelled using 
waterproof marker on non-peelable labels. 
HISTOPATHOLOGY 
All tissues collected at autopsy were examined after 
fixation, and, with reference to the autopsy report, appro- 
priate samples were trimmed. All samples were processed 
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using an automated wax-embedding technique and stained with 
haematoxylin and eosin. 
Microscopic examination of the sections was carried out 
with reference to the autopsy report, every attempt being 
made to identify the histological nature of the lesions 
seen at autopsy. 
Where tumours were seen each was identified according 
to the degree of differentiation, the probable cell-type 
of origin, presence or absence of invasion and metastasis 
and the general appearance of the cells. 
SAFETY 
As large volumes of nitrosamine solutions were involved 
in this study, safety was a major consideration. 
The unit in which the study was carried out was totally 
devoted to this function and contained a room for the 
preparation of solutions and its own cage-wash facilities. 
The risk attached to handling nitrosamine solutions can 
conveniently be divided into two areas, skin contact and 
inhalation. These two problems are considered separately 
below. 
Skin contact risk 
Protective clothing was provided for every member of 
staff employed in the unit, consisting of rubber boots, a 
gown, a hat, a face-visor and thick rubber gloves. This 
clothing was worn when all operations were being performed 
in the animal rooms; apart from handling the rats, when 
surgical gloves were worn. 
Any member of staff involved in the preparation of 
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solutions was required in addition, to wear a full-face 
gas-mask with an appropriate cannister attached. 
In addition to the protective clothing each member of 
staff received a set of rules and instructions governing 
the wearing of the clothing and defining the procedure to be 
followed in the event of accidental spillage or contact with 
the nitrosamine solutions. 
Occasionally spillages did occur and in these instances 
the animal room involved was immediately evacuated. The 
spillage was cleared by an individual in full protective 
clothing [including the respirator]. The method of clearing 
the spillage was to soak up the solution using paper tissue; 
this was then sealed in a polythene bag which was sealed 
in a second bag and taken for immediate incineration. The 
room was then locked and no access allowed for at least one 
hour (15 changes of air] . On no occasion did any staff 
report skin contact with the nitrosamine solutions. 
Inhalation risk 
Perhaps the highest risk area, as for skin contact, was 
the preparation room; the only area in the study where 
solutions containing more than 17 ppm nitrosamine were 
handled. This risk was considered adequately met by the 
use of respirators in this area. 
Throughout the rest of the facility the systems for 
dispensing the solutions and the drinking bottles attached 
to the cages were designed to mi ni muse risk in this respect. 
Analysis of the solutions demonstrated that there was no 
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detectable loss of nitrosamine from either the drinking or 
dispensing bottles. Coupled with the flow-rate of air in 
the animal rooms, the risk was regarded as minimal. 
A major source of risk in any situation is under-staffing, 
which tends to lead to short-cuts in procedures. Adequate 
staffing levels were ensured at all times during this study. 
Similarly no individual was permitted to work alone in the 
unit at any time. 
Procedures were developed for the disposal of all solid 
waste by incineration, as was a process for the neutrali- 
sation of waste solutions [page 41]. 
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CHAPTER FOUR 
RESULTS 
56 
Intake of Nitrosamine 
Samples of the body-weight and water-intake were analysed 
to determine the mg/kg/day intakes of both nitrosamines. As 
neither body weight nor water intake appeared to be affected 
by treatment the intakes were based on a mean figure for 
water intake derived from all groups. 
calculations is shown in table 4.1. 
Mortality 
The result of these 
Deaths occurred in the highest dose-groups of both 
nitrosamines after approximately 6 months of treatment. Sub- 
sequent mortality followed a dose-related pattern, with deaths 
occurring earlier at the higher doses (tables 4.2-4-53. In 
animals receiving less than 1056 ppb DEN or 1564 ppb DMN the 
mortality rate at all times was very similar to that of 
controls. Plots of cumulative mortality for both sexes of 
controls allow a median lifespan to be derived. This is 
estimated to be 920 days for males and 837 days for females 
(figures 4.1-4.2). 
Tumour incidences 
The majority of animals had at least one tumour at 
death and the incidence of all tumours found in each dose-group, 
classified by site is given in tables 4.6 to 4.9. Of the 
control animals 79'/0 of males and 94% of females had a tumour 
at death. 
A considerable number of tumours showed variation in 
incidence related to the dose of ni trosami ne . The incidence 
of tumours of pituitary, uterus and mammary tissue was 
significantly reduced, compared with controls, in the higher 
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Table 4.1 Calculated mean mg/kg/day intakes of DEN and 
DMN by animals receiving these ni trosami nes 
in their drinking water 
Concentration 
[ppm] 
mg/kg/day 
Males 
mg/kg/day 
Females 
0.033 0.002 0.003 
0.066 0.004 0.006 
0.132 0.008 0.011 
0.264 0.017 0.02 
0.526 0.03 0.05 
1.06 0.07 0.09 
1.58 0.10 0.14 
2.11 0.14 0.18 
2.64 0.17 0.23 
3.17 0.20 0.28 
4.22 0.27 0.37 
5.28 0.34 0.46 
6.34 0.41 0.55 
6.45 0.54 0.73 
16.9 1.08 1.47 
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Table 4.2 Cumulative mortality C%] of male rats receiving 
DEN in the drinking water 
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Table 4.3 Cumulative mortality C %I of male rats receiving 
DMN in the drinking water 
/ 
Concentration 
(PPM) 
200 
Accumulated 
400 600 
% mortality 
800 1000 
at day 
1200 1400 
0 [control) 2 4 7 29 70 99 100 
0.033 0 2 4 23 65 100 
0.066 0 0 2 29 71 100 
0.132 0 2 11 27 63 100 
0.264 0 2 2 33 71 98 100 
0.528 0 0 6 21 61 98 100 
1.06 0 0 11 36 79 98 100 
1.58 0 2 4 36 81 100 
2.11 0 0 8 31 73 100 
2.64 0 4 17 65 94 100 
3.17 0 2 21 56 100 
4.22 2 11 27 75 98 100 
5.28 0 6 71 100 
6.34 0 11 75 100 
8.45 2 29 100 
16.9 25 100 
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Table 4.4 Cumulative mortality [%] of female rats 
receiving DEN in the drinking water 
Concentration 
[ ppm] 200 
Accumulated 
400 600 
% mortality 
800 1000 
at day 
1200 1 400 
0 [control] 0 2 9 40 83 99 100 
0.033 0 0 8 33 86 100 
0.066 0 0 8 48 86 100 
0.132 0 0 11 46 94 100 
0.264 0 0 6 27 81 98 100 
0.528 0 4 15 56 98 100 
1.06 0 0 8 63 100 
1.58 0 2 21 92 100 
2.11 0 0 65 98 100 
2.64 0 2 86 100 
3.17 0 6 100 
4.22 0 38 100 
5.28 0 54 100 
6.34 0 90 100 
8.45 0 98 100 
16.9 12 100 
61 
Table 4.5 Cumulative mortality C%J of female rats 
receiving DMN in the drinking water 
Concentration 
(PPm) 
Accumulated % mortality at day 
200 400 600 800 1000 1200 1400 
0 (control] 0 2 9 40 83 99 100 
0.033 2 4 6 38 71 100 
0.066 2 2 13 48 79 98 100 
0.132 2 6 11 50 83 100 
0.264 0 0 2 42 83 100 
0.528 0 2 15 52 94 98 100 
1.06 2 2 11 44 78 100 
1.58 0 0 21 77 96 100 
2.11 0 2 25 73 100 
2-. 64 0 4 48 98 100 
3.17 0 4 65 98 100 
4.22 0 10 Be 100 
5.28 0 29 100 
6.34 0 27 100 
6.45 13 88 100 
16.9 56 100 
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dose-groups of both nitrosamines. This effect, along with 
the reduced incidence of several other tumour types, is an 
effect of treatment in that the animals died of treatment- 
-related tumours before the normal time of appearance of 
these spontaneous tumours. It clearly only represents a 
protective effect of treatment insofar as early death 
protects an individual from the hazards of growing old. The 
incidence of a small number of tumour types was increased in 
treated animals compared with controls. For diethyl- 
nitrosamine, treatment was related to increased incidence 
of tumours of: 
Liver 
0 esophagus 
Nasal epithelium. 
For dimethylnitrosamine the only site showing a treatment- 
-related increase in incidence of tumours was the liver. 
Treatment-related tumours 
The liver is a target-organ common to both nitrosamines. 
The full spectrum of change was seen in hepatocytes, with 
both DEN and DMN, ranging from nodular hyperplasia to totally 
anaplastic carcinoma. Hepatocellular tumours were common 
with both nitrosamines but were seen slightly more frequently 
with DEN. Other tumour types occurred originating from 
every cell-type present in normal liver. Haemangiomatous 
tumours were the next most common being seen more fre- 
quently following DMN treatment. While benign tumours of the 
biliary epithelium occurred with both nitrosamines only two 
malignant tumours of this origin were seen in the whole 
78 
study. The biliary cystadenomas were the commonest type of 
et 
tumour in the mid-dose groups of DMN. Finally, the Kupffer 
+ cells gave rise to a small number of tumours following 
treatment with either nitrosamine. The incidences of the 
different types of liver tumours are shown in tables 4.10 
to 4.13. Figures 4.3 to 4.6 illustrate the macroscopic 
appearance of the various tumour types. 
In diethylnitrosamine-treated animals tumours of the 
oesophagus and nasopharynx showed treatment-related 
incidences. The oesophageal tumours originated in the 
squamous epithelium and were frequently multiple, being 
clearly visible at autopsy as papillary growths protruding 
into the oesophageal lumen. The commonest site for such 
nodules was at the upper end of the oesophagus in the epi- 
glottis region, where a small nodule rapidly caused deterio- 
ration in the health of the animal. Nodules were also seen 
in these animals extending into the pharyngeal region, up 
to the base of the tongue. 
Malignant oesophageal tumours were frequently encountered 
in DEN-treated animals, diagnosed by their invasive properties, 
however, only one such tumour in the whole study showed 
evidence of metastasis. The response to treatment with DEN 
was perhaps more clearly seen with oesophageal tumours than 
with those of the liver, due to the total absence of spon- 
taneous tumours of this region in almost 2000 DMN-treated and 
control animals. A typical oesophageal lesion is shown in the 
photograph in figure 4.7. 
Tumours of the nasopharynx were not detected macro- 
scopically, however a few were seen on microscopic examination 
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Figure 4.3 Solid lobulated multifocal tumour. Diagnosed 
microscopically as a well-differentiated 
hepatocellular carcinoma. Hyperplastic nodules 
also present. [8448 ppb DEN 6 4239] 
Figure 4.4 Part cystic, part solid, multi focal tumour with 
very varied appearance. Diagnosed microscopically 
as two distinct tumours, hepatocellular carcinoma 
and haemangiosarcoma. [4224 ppb DMN 6 3529) 
84 
Figure 4.5 Totally cystic tumour, all cysts clear and 
transparent. Diagnosed microscopically as a 
biliary cystadenoma. [6336 ppb DMN 9 3797] 
Figure 4.6 Only slightly raised nodules on this liver but 
with the whole surface having a fine gravel type 
appearance. Diagnosed microscopically as a 
IR Kupffer-cell sarcoma. A haemangiosarcoma was 
also diagnosed. C3168 ppb DEN d 15B73. 
85 
op, 
4 
4 
Figure 4.7 Oesophagus showing 4 separate large nodules, 
each indicated [4] including one at the 
base of the tongue and another in a position 
where the epiglottis was obstructed 
[magnification x 2]. Diagnosed microscopically 
as papillomas and squamous cell carcinoma. 
86 
of the skulls. Again, no tumours of this type were seen in 
the controls. 
There was no other clear association between treatment 
and incidence of tumours at a specific site, however a 
complete time-related analysis was not carried out for all 
tumour types. 
.. \/ Relationship between dose and tumour incidence 
As DEN causes tumours at two sites [liver and oesophagus], 
the first examination of the data was to check if the 
preferred site changed with dose. A plot of incidence of 
liver and oesophageal tumours against dose showed that the 
incidence of tumours at the two sites followed a similar 
pattern in relation to dose [figures 4.8 and 4.91. There 
was a noticeable sex difference in that males seemed more 
likely to develop oesophageal tumours than females. It was 
concluded that the most useful analysis of the data from 
this study would be based on comparison of the total incidence 
of treatment-related tumours at different doses. Tables 4.14 
and 4.15 show the incidences of the tumours at each site and 
the incidence of animals with a tumour at both sites and the 
incidence of animals with a tumour at one or the other site. 
The incidences of fatal tumours will be discussed in a later 
section. 
Figure 4.10 shows the incidence of treatment-related 
tumours plotted against dose of DEN. Over much of the 
dose-range this plot runs close to 100'/o incidence and para- 
llel to the dose axis. At doses below 0.2 mg/kg/day 
incidence is reduced in a dose-related Manner. The incidence 
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of liver tumours in DMN-treated animals shows a similar 
picture [figure 4.113. 
Relationship between dose and time of tumour 
In view of the mortality data [table 4.2-4.5] an 
alternative analysis of this data might be based on time to 
tumour. 
If such an analysis is to be successfully carried out 
the measure of time to tumour used must be unambiguous. A 
common approach to this problem, is to use the time at which 
the tumour causes death. This involves pathologists in the 
exercise of determining cause of death, an exercise criti- 
cised by many and relished by none. If for a moment we 
examine the reasons for requiring the cause of death infor- 
mation, it is to allow a distinction to be made between 
fully developed tumours and those at a much earlier stage of 
development.. This distinction can be made without the need 
to define cause of death. Thus all tumours of similar size 
and development to those which were fatal are, for the purpose 
of analysis, regarded as fatal. Cumulative incidence plots 
have been drawn for the highest 4 doses of males given 
diethylnitrosamine [figure 4.12]. This plot illustrates the 
similarity in shape between the curves obtained at different 
doses, together with the shift to the right with decreasing 
dosage. A detailed account of a method of analysis of this 
data, based on the cumulative incidence of tumours, is given 
in the next chapter. 
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CHAPTER FIVE 
ANALYSIS OF RESULTS 
100 
Objective of analysis 
It is intended in this analysis to summarise the data 
from this study in such a way that it may be used to define 
the response that might be expected with any specified dose 
of nitrosamine. 
Standardisation of cumulative incidence 
For most of the high-dose groups the incidence of 
r 
treatment-related tumours is close to 100%. Any deaths with- 
out tumours are usually very early in the study when no 
tumours would be expected. As tumours do not suddenly appear 
it is necessary to define a specific point in tumour deve- 
lopment which will be comparable from one animal to another. 
The only practical point is the time at which the tumour 
causes the death of the animal. For all practical purposes, 
it was found that palpation was unlikely to detect tumours 
before the animal became ill. In all subsequent analysis 
this time will be referred to as 'the time of tumour' . As 
it is intended to compare the cumulative incidence curves at 
different doses a method has been developed to standardise 
these. The method used is based on that of Kaplan and Meier 
(1958) and permits the visualisation of the cumulative 
l 
distribution as it would be if there were no competing causes 
of death. The method works in the following way: 
On each day that a tumour occurs the following data is 
available; 
[i] Number of animals alive at start of that day [N] 
[ii] Number of deaths from a tumour during that day [X] 
101 
The tumour incidence rate for that day is then defined 
as: 
Xx 100 N 
On days when only deaths from other causes occur N is reduced 
but no incidence is calculated, e. g: 
Death Death 
No. of Tumour rate 
Adjusted 
Day from without '; cumulative 
tumour tumour Survivors 
for day incidence 
12 10 - 
21 8' 
gx 
100 = 12.5% 12.5% 
3272x 100 = 28.6% 37.5%a 
425-- 
5333x 100 = 100% 100.0% 
aValue calculated as: 
((100_- 12.53 x 28.6 
+ 12.5 
100 
The cumulative distributions adjusted in the above manner 
i 
are shown for the highest doses of each sex of each 
ni trosami ne in figures 5.1 - 5.4. 
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Median Time of Tumour 
Part of the summary of the data from this study is to 
derive a relationship between the time of tumour and dose of 
nitrosamine. The most convenient summary of time of tumour 
is the median time for each group, which is the time at which 
50% of the animals in that group are dead with a treatment- 
-related tumour [t50). Values for this time [t50) were 
obtained directly from the cumulative plots for all high-dose 
groups. These values plotted against dose using loge scales 
on both axes are shown in figures 5.5 and 5.6. A line was 
fitted to these plots by linear regression. From this linear 
regression a set of predicted median times was obtained for 
all groups. These are shown in tables 5.1 and 5.2, compared 
with the observed values. A correlation coefficient was 
calculated for the goodness of fit of the regression lines 
and was better than 0.99 in all cases. 
Summarising the Cumulative Distribution 
While the plot of median time against dose is useful in 
illustrating the existence of a relationship between dose and 
time of tumour, it is an incomplete summary of the data. In 
order to summarise the whole relationship it is necessary to 
incorporate some measure of the distribution of tumours about 
the median time. 
A casual observation made upon the data provided the 
basis for the next stage of the analysis. It was noted that 
on a log/ log plot of median times of tumour against dose, if 
time to 10% or 90% tumours was plotted these gave lines para- 
11 el to that given by median time but set to the left and 
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Fig. 5.5 RELATIONSHIP BETWEEN DOSE OF 
DIETHYLNITROSAMINE AND TIME OF TUMOUR 
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Fig. 5.6 RELATIONSHIP BETWEEN DOSE OF 
- DIMETHYLNITROSAMINE AND TIME OF TUMOUR 
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right respectively. 
It was discovered that this is equivalent to the 
observation that the time taken to reach x% tumours is a 
constant proportion of the time taken to reach 50% tumours. 
This feature can therefore be used to describe the cumu- 
lative distribution for any dose of the particular ni trosami ne . 
For each sex and each of the highest 6 treatment groups, the 
times that tumour incidence reached the following cumulative 
incidences were read from the graphs: 
2% 10'/0 ; 20% 
30% 40% 
. 
60% ; 70% 80% 
90% ;1 00'/ . 
The ratio between each of those times and t50 was 
calculated. For each sex of each nitrosamine all the ratios 
for each incidence point were meaned. Comparison of the 
results for both sexes on each nitrosamine should produce 
similar curves, thus the data from both sexes were pooled to 
give a single curve for each nitrosamine. These are shown 
in figures 5.7 and 5.8 and are subsequently referred to as 
the Standard Curves for each ni trosami ne. 
Use of the Summary 
The combination of the relationship between dose and 
time of tumour and the standard curves allows a complete 
summary of the distribution of tumours at any dose of either 
DMN or DEN. The predicted distribution of tumours in time 
for any dose is derived by the following process: 
[i] obtain the value for the t50 from the line 
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Fig. 5.7 Standard curve for the cumulative incidence 
of treatment-related tumours 
in DEN-treated rats. 
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Fig. 5.8 Standard curve for the cumulative incidence 
of treatment-related tumours in 
DMN-treated rats. 
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relating dose to median tumour time. 
[ii] Using the proportions of the standard curve 
as set out in table 5.3 below, the times that 
cumulative tumour incidence reaches 2,10,20, 
30,40,60,70,80 and 90% can be obtained. 
Table 5.3 Ratio between median tumour time [ t501 and time 
at which specified cumulative tumour incidences 
are reached 
Ratio between t50 and time cumulative tumour incidence 
reaches: 
2% 10% 20% 30% 4 0%0 50'% 60% 70% 80% 90% 
DEN 0.697 0.816 0.891 0.935 0.968 1 1.029 1.059 1.098 1.137 
MN 0.570 0.748 0.850 0.910 0.951 1 1.054 1.102 1.154 1.215 
Application of the standard curves for each nitrosamine to 
the calculated t50 values produces a set of curves as shown in 
figure 5.9. These demonstrate a similar pattern to that seen 
in the original data but are in fact of little value in pre- 
dicting events at low doses, where tumour incidence is 
certainly considerably less than 100°h. The simplest reason 
for tumour incidence to be lower than 100% is that a pro- 
portion of the animals die before the time that tumours appear. 
To explore the contribution of natural mortality, a technique 
was developed to correct the predicted cumulative tumour 
incidence curve at any dose, for this additional influence. 
Correction of Predicted Curves for Natural Mortality 
The estimate of expected natural mortality is based on 
the cumulative mortality data from the relevant control group. 
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The lif espan was divided into a series of 50-day intervals 
starting at day 0, the first day of treatment, and ending 
at day 1400 when the last rat had died. For each interval 
the expected death rate within that interval was derived 
from the cumulative mortality data as below: - 
MS =% Cumulative mortality at start of interval 
ME =% Cumulative mortality at end of interval 
SS =% Survival at start of interval [SS = 100 - MS] 
DR = Death rate C%] within interval 
ME 
- 
MS 
OR =x 100 
SS 
Thus OR% of animals alive at the start of the interval 
will be dead at the end of the interval. 
By a similar calculation, using values obtained from the 
predicted cumulative tumour incidence curve, the expected 
tumour rate within each interval was derived: 
TS =% Cumulative tumour incidence at start of interval 
TE _% Cumulative tumour incidence at end of interval 
SS =% Surviving tumour-free at start of interval 
TR = Tumour rate C% I within interval. 
TE - TS 
TR=x 100 
SS 
Thus T9% of animals surviving tumour-free at the start 
of the interval will have died from a tumour by the end of 
the interval. 
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The two rates DR and TR are assumed to act totally 
independently within each interval and are regarded as 
competing for the death of the animals. The following 
example in table 5.4 demonstrates how these rates can be 
applied to a hypothetical animal population to give expected 
values for the number of animals dying without tumours, and 
the number dying from tumours. 
The figure given for number of survivors at the start 
of each interval [N) is calculated by subtracting the 
predicted numbers of deaths, both from tumours and other 
causes, in the previous interval from the number alive at 
the start of that interval. An allowance is made for the 
fact that regarding the two rates OR and TR as operating 
independently will lead to some animals being predicted as 
killed twice [i. e. from tumour and other causes in the same 
interval]. Thus for interval i where preceding interval 
is i-1: 
TRi-1 x DR i-1 x 
Ni-1 
10000 
where A. 
and B. 
1 
DR. x N. 
100 
TR. x N. 
100 
Calculations similar to the one shown above were performed 
for the predicted curves for all doses used on the study, where 
the first tumour was predicted to occur within the normal 
maximum lifespan [1400 days]. The resultant calculated 
incidences are compared with observed values in figures 
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5.10 - 5.13. In all cases the predicted curves fit the 
observed data sufficiently closely for the lack of tumours 
at low doses to be considered totally explicable by the 
failure of animals to survive in sufficient numbers to a 
time when those doses would induce a detectable incidence of 
tumours0 
While various alternative explanations could be 
offered to explain the decline in incidence at low doses 
the results of this analysis confirm that the data from this 
study was not incompatible with the following assumptions: 
[i] That all doses of both DEN and DMN used in this 
study have the potential to induce tumours in 100% 
of exposed animals if those animals survive long 
enough for the tumours to appear. 
[ii] The failure of animals to survive long enough is 
sufficient explanation for all incidences of 
tumours less than 100% 
[iii] The major response factor in any dose-response 
relationship with these nitrosamines is time. 
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CHAPTER SIX 
DISCUSSION 
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Tumour Types and Incidences 
In general, the type and site of the tumours induced 
in this study was similar to that described for DEN by 
I Druckrey [1967] and for DMN by Barnes and Magee C19561. For 
the first time, however, this study demonstrated the potential 
of these carcinogens to cause tumours of every cell type 
present in the liver. For all cell types, apart from the 
biliary epithelium both malignant and benign tumours were 
seen. In the case of the biliary epithelium, while both 
ni tro sami nes induced numerous benign cystadenomas very few 
malignant tumours were seen. 
The pattern of the biliary tumours, particularly in the 
mid-dose OMN groups, where they were the commonest lesion, 
may be a confusing factor in the analysis of the dose-response 
pattern in these groups. While all other fatal, induced 
tumours show similar time distributions at similar doses the 
biliary cystadenomas appear to become palpable and thus 
fatal earlier at each dose than tumours of other cell types. 
It is likely, therefore, that the dose-response relationships 
derived from this data would overestimate the incidence of 
liver tumours at doses below those at which the biliary 
tumours are common. 
With DEN the tumours of the oesophagus showed a clear 
cut-off point below which dose no lesion of the oesophageal 
epithelium was seen. The main reason for the clarity of this 
point is the total absence of spontaneous tumours of this 
epithelium in untreated rats. While such a clear cut-off 
indicates some form of effect threshold for this tissue 
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this may have many origins; and cannot be considered relevant 
to discussions of true thresholds of effect when other 
organs in the same animals were affected by treatment. It 
is possible that below a dose of 500 ppb the liver succeeds 
in metabolising so much of the ingested nitrosamine that the 
effective dose to the oesophagus is reduced to a value close 
to zero. It is also possible that a proportionate dose of 
nitrosamine does reach the oesophagus but is too small to 
cause sufficient damage for the repair processes to be 
overwhelmed. It is likely that a prime requirement for 
oesophageal tumours is a dose high enough to bring about 
epithelial hyperplasia and ulceration [Napalkov and Pozharisski, 
1969] and that the tumour development does not proceed in the 
absence of stimulus until a relatively late stage. This would 
separate the tumour development process in the oesophagus from 
that in other tissues such as the liver. With nitrosamines 
there is little evidence for the need for hepatocellular 
hyperplasia as a precursor of malignant tumours, although this 
is known to be the mechanism of hepatocarcinogenesis with some 
other chemicals [e. g. Ponceau MX]. It is therefore concluded 
that the cut-off point for oesophageal tumours does not 
indicate the existence of an overall threshold of response to 
DEN. The details of tumour response in the liver show a 
background of spontaneous tumour incidence in untreated 
animals, making the detection of the very few additional 
tumours, predicted to occur at the lowest doses, impossible. 
At most doses of DEN the tumours of the two main target 
sites appeared to compete for the death of the animal, thus 
at these doses a large proportion of the treated animals 
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had tumours at both sites. 
Tumour Time Related to Dose 
The results of the studies with DEN are compared 
graphically in figure 6.1 
study by Druckrey [ 1967D. 
with the data generated in an earlier 
The median time of tumour data 
obtained by Druckrey are plotted on the same axes as the 
dose-response lines for DEN from this study. The closeness 
of fit would tend to suggest that rat strain plays little part 
in the pattern of dose-response. There is in addition little 
indication of any change in the relationship between dose and 
time of tumour over the whole range of doses studied a 
The analysis of this study reported in chapter 5, 
indicates that the lack of a detectable effect at the lowest 
doses of this study could be explained by the inability, of 
groups of the size used, to detect the low incidences of 
tumours which might be expected. While this explanation is 
that which requires least assumptions it is by no means the 
only one that can be applied to these results. If it is 
assumed that the pattern of dose-response changes at a point 
just below the level of detectable effects then a wide 
range of conclusions can be drawn. Three alternative extra- 
j polations are given in figure 6.2. Alternative [a] assumes 
that the relationship alters at low doses such that there is 
little effect of reducing dose on median time of tumour. 
Alternative [b] assumes that the experimentally determined 
relationship remains valid at all doses, while [c) assumes 
that the relationship alters at low doses to allow reducing 
dose to increase time of tumour at a greater rate than before. 
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FIGURE 6.1 A COMPARISON OF THE RESULTS OF DRUCKREY 
[19671 WITH THE DOSE-RESPONSE LINE FOR DEN 
IN FEMALE RATS FROM THE BI@RA STUDY 
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The only justification for choice in this situation is lack 
of information. There is no evidence that there is any 
change in the relationship at low doses thus alternative 
[b] has been assumed throughout analysis of this study, 
however, some consideration is given to other alternatives 
below. 
Factors That May Modify Relationship 
A wide range of influences may play a part in altering 
the pattern of dose-response at very low doses. The type of 
changes that may decrease the chance of carcinogenic change 
are: 
[i) A metabolic shift from activation to detoxification 
at low doses [i . e. at high doses the detoxification 
pathway is saturated) 
(ii] Ability of scavenger molecules such as glutathione 
to contain the quantity of radicals generated. 
[iii] Ability of DNA repair mechanisms to keep up 
with the rate of damage. 
There are however certain alternative changes that may act in 
the opposite direction: 
[i] A metabolic shift towards greater proportional 
activation at low doses [i. e. that a first stage 
activation process has been saturated at high 
doses with the bulk of ingested nitrosamine being 
detoxified] 
[ii] At high doses it is likely that DNA repair 
processes are induced by the carcinogen. At low 
doses the absence of such an induction may lead 
to a relatively greater effect from these doses. 
1 41 
Unfortunately, although there is evidence for several 
1 
pathways in nitrosamine metabolism and effects on DNA repair 
no firm conclusions can be reached as to the direction of 
such effects or about the 'in vivo' doses at which they may 
occur. It is therefore assumed that these factors act to 
cancel out each other-'s effects. 
Alternative Approaches to Analysis of this Data 
A wide range of models exist at present, all seeking to 
provide the best method of analysing carcinogenicity data 
[Peto, 1980; Hartley and Sielkin, 1977; Albert and Altschuler, 
19733. Each of these methods has its basis in certain 
assumptions concerning the nature of chemical carcinogenesis 
and thus the mathematics of the relationship between dose 
and response. Over the observable range of tumour incidence 
all the models are likely to be capable of providing a good 
fit to the data. At the low doses, where any calculation of 
effect is based on extrapolation of the model, there is little 
to choose between the various approaches although each offer 
different conclusions. This study provided a unique opportunity 
to avoid the use of established models by an analysis guided 
by the biology of the process involved, where assumptions 
have been kept to the minimum necessary to provide an 
adequate summary or explanation of the data. An independent 
appraisal of this data is soon to be completed by Richard 
Peto of Oxford. 
Extrapolation from Rat to Man 
If the extrapolation from high to low dose in rats is 
considered to be uncertain the process of extrapolating 
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quantitatively from rat to man is almost totally a matter 
of guided guesswork. 
Some thought needs to be given to the equivalence of 
exposure levels. In vitro metabolic studies by Montesano 
and Magee C1970] using DMN indicated that for this nitro- 
samine, under the conditions chosen, the rate of metabolism 
was similar for rat and man. As liver weight represents a 
roughly similar proportion of total body weight in the two 
species a dose administered as mg/kg body weight is likely 
to present a similar dose to each cell of the target tissue. 
Generally the rate of xenobiotic oxygenation is 
linearly related to body-weight [Parke, 19821, and 
as such takes place more rapidly in rat than in man. As 
ni trosami nes are activated by oxidative metabolism it is 
likely that activation of a given daily dose will be greater 
in rats than man, leading to earlier effects in the former 
species. It is possible however that the difference in 
li fespans of the two species may to a great extent compen- 
sate for these differences in metabolism when lifetime 
carcinogenic risks are considered. As it is not yet certain 
which enzyme is involved in nitrosamine activation it is 
difficult to put any quantitative relationship on the 
species differences in rates and extents of metabolic 
activation. Thus the same units of dose-rate can be used 
for rat and man. 
A second consideration is the time taken for tumours 
to appear. It is likely, from other experience of the 
carcinogenic process, that the time from first treatment 
to first tumour at a given dose is not an absolute quantity 
1 43 
regardless of species. It is more likely that this 
time-period is in some way related to average life-span. It 
is proposed therefore to assume that median lifespan in the 
rat is equivalent to median human lifespan for the purposes 
of extrapolation. 
Although a whole range of other factors may be involved 
in determining the response to nitrosamines it is considered 
that, in general, human diversity may well be as great as 
the species differences, thus little account of these factors 
can be taken in extrapolating from rat to man. It is con- 
si dered that where species differences occur the rat is 
likely to represent the most adverse response that might be 
expected in a human population and is a valid model for 
calculating maximum expected human risks. 
Calculation of Expected Human Risk 
By its nature, the process of extrapolation from 
high-dose exposure in animals to low-dose human exposure 
is open to a variety of techniques each with their own merits. 
The extrapolation that follows is an extension of the analysis 
described previously and is based on a number of assumptions 
that are identified when appropriate. 
The first stage of analysis is based on the assumption 
that the relationship established between dose and time 
of tumour for experimental doses, holds true for all doses. 
The regression lines obtained for the plots of median time 
of tumour against dose have been used to calculate median 
tumour times appropriate to doses of 0.1 43 and 1.43 pg/kg/day, 
these being equivalent to human exposure of 10 or 100 rg per 
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day at a body weight of 70 kg. [Table 6.13 
As might have been expected the predicted median times 
of tumour lie well beyond the normal lifespan of the animals 
used. However, the tumours at any dose are distributed in 
time. The pattern of this distribution was summarised from 
the experimental data in the Standard Curves [figures 5.7 
and 5.81. Assuming that the pattern of the distribution 
continues to be appropriate at the doses equivalent to human 
exposure then the predicted cumulative incidence curves for 
these doses will be based on the following points [Table 6.23. 
Due to the size of the experimental groups the derived 
curve for distribution around the median cannot directly be 
used to predict the time at which incidences lower than 2% 
are reached. If it is assumed that the risk approaches 0 at 
zero dose then the lower end of the distribution can be 
extrapolated to give some estimate of tumour risk within the 
normal lifespan. The regression of loge Cumulative incidence 
on log 
e 
time showed a correlation coefficient of > 0.99 in 
all cases and this relationship has been used to extrapolate 
the lower end of the cumulative distribution so that estimates 
of risk can be obtained for any age. The cumulative incidence 
of tumours expected at median lif espan and at the time that 
the last animal died is given in Table 6.3. 
The predicted cumulative incidences within rat lifetimes 
can be used to estimate the magnitude of the human risk from 
these doses of nitrosamine. This use does however depend on 
the following assumptions: 
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Table 6.1 Estimates of median time of tumour by extrapolation 
from experimental data in rats 
Estimated median time of tumourt at a dose of 
0.1 43 p g/ k g/ day 1.43 p g/ k g/ day 
Male DEN 17323 6007 
Female DEN 14980 5278 
Male DMN 141337 27605 
Female DMN 38017 10502 
time in days from first dose of nitrosamine. 
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Table 6.2 Predicted distribution of tumours at very low 
doses of nitrosamines 
Cumulative 
Incidence 
Time [days from first dose] that incidence reached 
C%3 
d DEN DEN d DMN DMN 
0.1 43 }. i g/ kg 
per day 
2 12074 10441 80562 21670 
10 14136 12224 105720 28437 
20 15435 13347 120136 32314 
30 16197 14006 128617 34595 
40 16769 14501 134411 36154 
50 17323 14980 141337 38017 
1.43 pg/kg 
per day 
.2 4187 3679 
15735 5986 
10 4902 4307 20649 7855 
20 5352 4703 23464 8927 
30 5617 4935 25121 9557 
40 5815 5109 26252 9987 
50 6007 5278 27605 10502 
1 47 
Table 6.3 Predicted cumulative incidence of tumours within 
rat lifespan at very low doses of DEN and DMN 
Dose [}ag/kg/ day] Cumulative incidence 
[%] at day 
850 1300 
0.143 DEN 9 3.93 x 10 
10 1.75 x 10 
8 
1.43 DEN 9 4.40 x 10 
6 1.96 x 10-4 
0.143 DMN ý 1.59 x 10 
8 1.84 x 10 
7 
1.43 DMN 9 2.64 x 10 
5 
3.05 x 10 
4 
Cumulative incidence C%] at day 
Dose [)-jg/kg/day] 
920 1 300 
0.143 DEN d 2.18 x 10 
10 
4.79 x 10 
9 
1.43 DEN d 2.81 x 10 
6 6.19 x 10-5 
0.143 DMN d 1.29 x 10 
11 
9.49 x 10-11 
1.43 DMN d 1.58 x 10 
7 1.16 x 10 
6 
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[i] That the time taken for a given dose of nitrosamine 
to induce tumours is related to the natural lifespan of the 
species involved. For this purpose the median lifespan of 
rats and humans is assumed to be: 
Sex Rat Human 
Male 920 days 70 years 
Female 850 days 75 years. 
[ii) That there is no difference in sensitivity to the 
nitrosamines between man and rat, and that all the charac- 
teristics of the relationship between dose and time of 
tumour established for rats hold true for humans. 
The cumulative incidence data cannot themselves be 
used to estimate human risk. First of all the expected 
incidence of tumours is calculated for the two intervals, 0 
to median lifespan and median to end of lifespan. 
calculated as: 
Incidence of tumours 
expected within interval 
as [%] of average numbers = CIE - IS] x 
of animals alive in 
interval 
This is 
100 
S [SS SE] S2 
IS= Cumulative Incidence at start of interval 
IE = Cumulative Incidence at end of interval 
SS = Survival at start of interval 
SE = Survival at end of interval. 
The age distribution of the human population of the U. K. 
[CSO, 1980) shows the numbers of individuals alive in the 
1 49 
intervals corresponding to those used in Table 6.4 as: 
0-Median 51.559 x 106 Median-End 4.346 x 106 
From table 6.4 the extrapolated data for DMN-treated females 
indicates the greatest incidence of tumours, with a figure 
of 4.69 x 10 -3 tumours/10 
6 
individuals/ year up to median 
li fespan and 0.444 tumours/10 
6 
individuals/year over the 
remaining. -years. 
With the population age-distribution 
defined above this would indicate a total incidence of 2 
tumours/year, in the whole U. K. population, due to nitrosamines. 
As all the other extrapolations yield predicted incidences 
considerably lower than this it may be concluded, subject to 
all the assumptions identified, that exposure of the U. K. 
population to 100 »g/persorry/ day of nitrosamines equivalent 
to DMN is unlikely to increase human death-rates by a 
detectable amount. 
Conclusions 
The magnitude of the calculated human risk may, if all 
the assumptions are agreed, provide some measure of assurance 
that current levels of exposure to nitrosamines are not a 
major cause of death in the U. K. population. 
It is clear, however, that the risk is finite, which 
poses two questions. Firstly nitrosamines cannot be 
considered in isolation; it is known that two or more 
carcinogens having the same target organ can have an additive 
effect [Newberne and Connor, 1980] . The predicted level of 
response to 100 pg/ day of nitrosamine would leave the 
population on the threshold of response to a whole range of 
other carcinogens. 
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Table 6.4 Predicted incidence of tumours 
D [ /k /d ] 
Predi cted incidence [%] within interval 
ose pg g ay 
0- MEDIAN MEDIAN - END 
0.143 DEN 9 5.24 x 10-10f 6.84 x 10-8 
1.43 DEN 9 5.87 x 10 
6 7.66 x 10 
4 
0.143 DMN q 2.12 x 10 
8 6.72 x 10 
7 
1.43 DMN q 3.52 x 10 
5 1.11 x 10-3 
0.143 DEN d 2.91 x 10 
10 1. B3 x 10 
8 
1.43 DEN d 3.75 x 10 
6 2.36 x 10 
4 
0.143 DMN d 1.72 x 10 
11 3.28 x 10-10 
1.43 DMN d 2.11 x 10 
7 4.01 x 10 
6 
Figures are the percentage of the average number of 
animals alive in the interval that can be expected to die 
from a treatment-related tumour in that interval. 
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A second thought, arising from the results of 
extrapolation relates to the end-point used in the animal 
studies described above. The time of tumour was the time 
at which the tumour brought about the death of the animal. 
No measure has been obtained, in this or any other study of 
the relationship between dose of carcinogen and tumour 
development time. The loss of a human life through cancer 
has its obvious sadness but it is the suffering that precedes 
death that has made cancer the dread of so many. No estimate 
is possible from this study of the amount or extent of 
suffering that may derive from ni trosami ne exposure. 
This study adds a step to the understanding of the 
risks posed by low levels of chemical carcinogens. Any 
further progress must come from a general understanding of 
the process of carcino genesis and a detailed study of the 
fate 'in vivo' of very low doses of carcinogens. 
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